NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$40.87 +0.86 (+2.15 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$40.87
Today's Range$39.56 - $41.34
52-Week Range$30.10 - $67.10
Volume796,824 shs
Average Volume2.07 million shs
Market Capitalization$2.63 billion
P/E Ratio-8.50
Dividend YieldN/A
Beta1.48

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers. It is also developing PRT2761, which is in Phase 2 for allergic conjunctivitis; and PCSK9 inhibitor in pre-clinical study for hypercholesterolemia. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Debt-to-Equity Ratio0.35
Current Ratio7.59
Quick Ratio7.53

Price-To-Earnings

Trailing P/E Ratio-8.50
Forward P/E Ratio-7.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.55 million
Price / Sales119.29
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book8.68

Profitability

EPS (Most Recent Fiscal Year)($4.81)
Net Income$-286,090,000.00
Net Margins-1,364.89%
Return on Equity-109.35%
Return on Assets-65.49%

Miscellaneous

Employees252
Outstanding Shares65,820,000

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals (NASDAQ:PTLA) issued its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.22) by $0.06. The biopharmaceutical company had revenue of $6.64 million for the quarter, compared to analyst estimates of $3.20 million. Portola Pharmaceuticals had a negative return on equity of 109.35% and a negative net margin of 1,364.89%. The business's quarterly revenue was up 29.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.74) EPS. View Portola Pharmaceuticals' Earnings History.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Portola Pharmaceuticals.

What price target have analysts set for PTLA?

7 Wall Street analysts have issued 12 month target prices for Portola Pharmaceuticals' stock. Their predictions range from $46.00 to $80.00. On average, they expect Portola Pharmaceuticals' stock price to reach $64.00 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:
  • Mr. William Lis, CEO, Pres & Director (Age 54)
  • Ms. Mardi C. Dier, CFO & Exec. VP (Age 54)
  • Dr. John T. Curnutte, Exec. VP of R&D (Age 66)
  • Mr. Tao Fu, Chief Commercial & Bus. Officer & Exec. VP (Age 46)
  • Mr. John B. Moriarty Jr., Exec. VP & Gen. Counsel (Age 50)

Has Portola Pharmaceuticals been receiving favorable news coverage?

Headlines about PTLA stock have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a coverage optimism score of 0.05 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.09%), Kornitzer Capital Management Inc. KS (1.63%), Zevenbergen Capital Investments LLC (1.26%), Northern Trust Corp (1.12%), JPMorgan Chase & Co. (1.02%) and Pinnacle Associates Ltd. (0.65%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Which major investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Royal Bank of Canada, Highland Capital Management LP, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Artal Group S.A., Principal Financial Group Inc. and Principal Financial Group Inc.. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Which major investors are buying Portola Pharmaceuticals stock?

PTLA stock was bought by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, UBS Group AG, Sector Gamma AS, Russell Investments Group Ltd., Amundi Pioneer Asset Management Inc., Zevenbergen Capital Investments LLC, Delek Group Ltd. and RMB Capital Management LLC. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $40.87.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $2.63 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (PTLA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  484
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Portola Pharmaceuticals (NASDAQ:PTLA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Portola Pharmaceuticals in the last 12 months. Their average twelve-month price target is $64.00, suggesting that the stock has a possible upside of 56.59%. The high price target for PTLA is $80.00 and the low price target for PTLA is $46.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.863.002.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $64.00$66.6667$68.1667$67.6667
Price Target Upside: 56.59% upside100.62% upside51.79% upside33.86% upside

Portola Pharmaceuticals (NASDAQ:PTLA) Consensus Price Target History

Price Target History for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ:PTLA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018OppenheimerSet Price TargetBuy$80.00LowView Rating Details
5/7/2018Morgan StanleyReiterated RatingPositive ➝ Equal Weight$31.00 ➝ $46.00HighView Rating Details
5/7/2018CitigroupBoost Price TargetBuy$64.00HighView Rating Details
3/13/2018William BlairReiterated RatingBuyMediumView Rating Details
3/13/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$53.00 ➝ $49.00HighView Rating Details
12/1/2017Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$75.00HighView Rating Details
6/26/2017CowenBoost Price TargetOutperform$45.00 ➝ $70.00HighView Rating Details
2/24/2017CIBCUpgradeMarket Perform ➝ OutperformN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Portola Pharmaceuticals (NASDAQ:PTLA) Earnings History and Estimates Chart

Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ:PTLA) Earnings Estimates

2018 EPS Consensus Estimate: ($5.72)
2019 EPS Consensus Estimate: ($1.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.54)($1.53)($1.54)
Q2 20182($1.53)($1.48)($1.51)
Q3 20182($1.48)($1.37)($1.43)
Q4 20182($1.31)($1.20)($1.26)
Q1 20191($0.82)($0.82)($0.82)
Q2 20191($0.56)($0.56)($0.56)
Q3 20191($0.25)($0.25)($0.25)
Q4 20191$0.05$0.05$0.05

Portola Pharmaceuticals (NASDAQ PTLA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($1.49)N/AView Earnings Details
5/9/2018Q1 2018($1.22)($1.28)$3.20 million$6.64 millionViewN/AView Earnings Details
2/28/2018Q4 2017($1.46)($1.41)$3.71 million$9.80 millionViewListenView Earnings Details
11/6/2017Q3 2017($1.49)($1.41)$4.71 million$3.83 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.10)($1.22)$4.28 million$3.79 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
11/9/2015Q3 2015($1.24)($1.05)$2.40 million$2.91 millionViewN/AView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.4150 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
11/5/2013Q3 2013($0.68)($0.53)$2.00 million$2.77 millionViewN/AView Earnings Details
8/15/2013($0.72)($1.47)$2.00 million$2.60 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Portola Pharmaceuticals (NASDAQ:PTLA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Portola Pharmaceuticals (NASDAQ PTLA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 86.16%
Insider Trading History for Portola Pharmaceuticals (NASDAQ:PTLA)
Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ PTLA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2018Tao FuEVPSell1,135$38.47$43,663.4518,346View SEC Filing  
12/15/2017Henry Ward WolffDirectorSell12,000$47.00$564,000.00View SEC Filing  
7/18/2017John T. CurnutteInsiderSell10,000$65.00$650,000.00View SEC Filing  
7/18/2017Tao FuEVPSell5,812$65.00$377,780.00View SEC Filing  
7/11/2017Mardi DierVPSell23,350$60.00$1,401,000.00View SEC Filing  
6/28/2017William LisCEOSell269,299$55.43$14,927,243.57View SEC Filing  
6/27/2017Mardi DierVPSell93,392$55.46$5,179,520.32View SEC Filing  
6/26/2017John T. CurnutteInsiderSell60,000$57.88$3,472,800.00View SEC Filing  
6/26/2017Tao FuEVPSell7,000$57.14$399,980.00View SEC Filing  
6/23/2017Charles J. HomcyDirectorSell120,803$53.06$6,409,807.18View SEC Filing  
6/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,700,000$34.40$58,480,000.00View SEC Filing  
6/1/2017Jeffrey W BirdDirectorBuy119,442$31.85$3,804,227.703,000View SEC Filing  
4/11/2017William LisCEOSell6,750$36.06$243,405.004,730View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.5018,333View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00706View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.0024,824View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.0029,824View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Portola Pharmaceuticals (NASDAQ PTLA) News Headlines

Source:
DateHeadline
Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®Portola Pharmaceuticals Receives $100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®
finance.yahoo.com - May 24 at 8:59 AM
Portola Takes Another Big Step ForwardPortola Takes Another Big Step Forward
finance.yahoo.com - May 22 at 8:54 AM
William Blair Equities Analysts Decrease Earnings Estimates for Portola Pharmaceuticals (PTLA)William Blair Equities Analysts Decrease Earnings Estimates for Portola Pharmaceuticals (PTLA)
www.americanbankingnews.com - May 21 at 2:00 AM
 Analysts Anticipate Portola Pharmaceuticals (PTLA) Will Post Quarterly Sales of $5.73 Million Analysts Anticipate Portola Pharmaceuticals (PTLA) Will Post Quarterly Sales of $5.73 Million
www.americanbankingnews.com - May 20 at 2:46 AM
-$1.51 EPS Expected for Portola Pharmaceuticals (PTLA) This Quarter-$1.51 EPS Expected for Portola Pharmaceuticals (PTLA) This Quarter
www.americanbankingnews.com - May 18 at 5:29 PM
Portola Pharmaceuticals (PTLA) PT Set at $80.00 by OppenheimerPortola Pharmaceuticals (PTLA) PT Set at $80.00 by Oppenheimer
www.americanbankingnews.com - May 18 at 3:53 PM
Portola Pharmaceuticals (PTLA) CEO William Lis on Q1 2018 Results - Earnings Call TranscriptPortola Pharmaceuticals' (PTLA) CEO William Lis on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 9:29 AM
Buy Diamondback Energy On Declines - Cramers Lightning Round (5/11/18)Buy Diamondback Energy On Declines - Cramer's Lightning Round (5/11/18)
seekingalpha.com - May 14 at 9:37 AM
Portola Pharmaceuticals (PTLA) Expected to Earn Q2 2018 Earnings of ($1.53) Per SharePortola Pharmaceuticals (PTLA) Expected to Earn Q2 2018 Earnings of ($1.53) Per Share
www.americanbankingnews.com - May 14 at 1:56 AM
Q2 2018 EPS Estimates for Portola Pharmaceuticals Lowered by Analyst (PTLA)Q2 2018 EPS Estimates for Portola Pharmaceuticals Lowered by Analyst (PTLA)
www.americanbankingnews.com - May 14 at 1:56 AM
Portola Pharmaceuticals (PTLA) Downgraded to Hold at ValuEnginePortola Pharmaceuticals (PTLA) Downgraded to Hold at ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM
Portola Pharmaceuticals Forecasted to Earn FY2020 Earnings of $1.97 Per Share (PTLA)Portola Pharmaceuticals Forecasted to Earn FY2020 Earnings of $1.97 Per Share (PTLA)
www.americanbankingnews.com - May 11 at 11:47 AM
Portola Pharmaceuticals: Elucidating The Ramifications Of The AndexXa ApprovalPortola Pharmaceuticals: Elucidating The Ramifications Of The AndexXa Approval
seekingalpha.com - May 10 at 9:12 AM
Portola Pharmaceuticals: 1Q Earnings SnapshotPortola Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:12 AM
Edited Transcript of PTLA earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of PTLA earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:12 AM
Portola Pharmaceuticals (PTLA) Releases Quarterly  Earnings Results, Misses Estimates By $0.06 EPSPortola Pharmaceuticals (PTLA) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 9 at 10:08 PM
Portola Pharmaceuticals beats by $0.24, beats on revenuePortola Pharmaceuticals beats by $0.24, beats on revenue
seekingalpha.com - May 9 at 4:53 PM
Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdatePortola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 4:53 PM
Is There An Opportunity With Portola Pharmaceuticals Inc’s (NASDAQ:PTLA) 33% Undervaluation?Is There An Opportunity With Portola Pharmaceuticals Inc’s (NASDAQ:PTLA) 33% Undervaluation?
finance.yahoo.com - May 9 at 9:06 AM
Brokers Offer Predictions for Portola Pharmaceuticals Q1 2018 Earnings (PTLA)Brokers Offer Predictions for Portola Pharmaceuticals' Q1 2018 Earnings (PTLA)
www.americanbankingnews.com - May 9 at 8:23 AM
Portola Pharmaceuticals (PTLA) Expected to Post Q3 2018 Earnings of ($1.24) Per SharePortola Pharmaceuticals (PTLA) Expected to Post Q3 2018 Earnings of ($1.24) Per Share
www.americanbankingnews.com - May 9 at 7:56 AM
Reader Inquiry: After Approval Is Portola Pharmaceuticals A Buy?Reader Inquiry: After Approval Is Portola Pharmaceuticals A Buy?
seekingalpha.com - May 8 at 4:52 PM
Portola Pharmaceuticals (PTLA) Given Average Rating of "Buy" by AnalystsPortola Pharmaceuticals (PTLA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 7 at 5:36 PM
Portola Pharmaceuticals (PTLA) Receives Equal Weight Rating from Morgan StanleyPortola Pharmaceuticals (PTLA) Receives Equal Weight Rating from Morgan Stanley
www.americanbankingnews.com - May 7 at 2:58 PM
Portola Pharmaceuticals (PTLA) Given a $80.00 Price Target at OppenheimerPortola Pharmaceuticals (PTLA) Given a $80.00 Price Target at Oppenheimer
www.americanbankingnews.com - May 7 at 2:57 PM
Portola Pharmaceuticals (PTLA) Given New $64.00 Price Target at CitigroupPortola Pharmaceuticals (PTLA) Given New $64.00 Price Target at Citigroup
www.americanbankingnews.com - May 7 at 1:15 PM
Why Portola Pharmaceuticals Skyrocketed 25.6% TodayWhy Portola Pharmaceuticals Skyrocketed 25.6% Today
finance.yahoo.com - May 5 at 9:18 AM
Portola Pharmaceuticals (PTLA) Stock Rating Upgraded by ValuEnginePortola Pharmaceuticals (PTLA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 5 at 2:43 AM
Portola Pharmaceuticals Inc. (PTLA) Is Up Sharply After FDA ApprovalPortola Pharmaceuticals Inc. (PTLA) Is Up Sharply After FDA Approval
www.nasdaq.com - May 4 at 4:46 PM
Rally on! Here’s Why Portola Pharmaceuticals (PTLA) Shares Jumped 20% TodayRally on! Here’s Why Portola Pharmaceuticals (PTLA) Shares Jumped 20% Today
finance.yahoo.com - May 4 at 4:46 PM
Portola Pharma Rips 20% Higher After FDA Approves Andexxa AntidotePortola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote
feeds.benzinga.com - May 4 at 3:28 PM
Mid-Afternoon Market Update: Dow Surges Around 400 Points; Portola Pharmaceuticals Shares Spike HigherMid-Afternoon Market Update: Dow Surges Around 400 Points; Portola Pharmaceuticals Shares Spike Higher
feeds.benzinga.com - May 4 at 3:28 PM
Portola Pharma (PTLA) Reports FDA Approval of AndexxaPortola Pharma (PTLA) Reports FDA Approval of Andexxa
www.streetinsider.com - May 4 at 8:58 AM
FDA OKs Portolas Andexxa; shares up 24% premarketFDA OKs Portola's Andexxa; shares up 24% premarket
seekingalpha.com - May 4 at 8:58 AM
Portola Pharmaceuticals (PTLA) Expected to Post Quarterly Sales of $4.30 MillionPortola Pharmaceuticals (PTLA) Expected to Post Quarterly Sales of $4.30 Million
www.americanbankingnews.com - May 3 at 4:52 AM
Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action DatesAttention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates
feeds.benzinga.com - May 1 at 4:10 PM
Options Traders Expect Huge Moves in Portola (PTLA) StockOptions Traders Expect Huge Moves in Portola (PTLA) Stock
www.zacks.com - May 1 at 9:05 AM
Todays Research Reports on Trending Tickers: Magellan Health and Portola PharmaceuticalsToday's Research Reports on Trending Tickers: Magellan Health and Portola Pharmaceuticals
finance.yahoo.com - May 1 at 9:05 AM
Zacks: Analysts Anticipate Portola Pharmaceuticals (PTLA) to Announce -$1.50 Earnings Per ShareZacks: Analysts Anticipate Portola Pharmaceuticals (PTLA) to Announce -$1.50 Earnings Per Share
www.americanbankingnews.com - May 1 at 5:31 AM
Apixaban Market Extensive Analysis of Supply And Demand, Revenue, Risk and Share 2018-2025Apixaban Market Extensive Analysis of Supply And Demand, Revenue, Risk and Share 2018-2025
www.prnewswire.com - April 30 at 4:44 PM
3 Small-Cap Biotech Stocks With Big Catalysts in May3 Small-Cap Biotech Stocks With Big Catalysts in May
www.nasdaq.com - April 30 at 4:44 PM
Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday ...Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday ...
www.globenewswire.com - April 30 at 4:44 PM
Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
finance.yahoo.com - April 30 at 4:44 PM
Portola Pharmaceuticals (PTLA) Scheduled to Post Earnings on MondayPortola Pharmaceuticals (PTLA) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 8:00 AM
Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib ...Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib ...
globenewswire.com - April 26 at 8:53 AM
Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical ...Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical ...
www.nasdaq.com - April 25 at 4:55 PM
Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingPortola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
feeds.benzinga.com - April 25 at 2:33 PM
Portola Pharmaceuticals (PTLA) Upgraded to Hold by BidaskClubPortola Pharmaceuticals (PTLA) Upgraded to Hold by BidaskClub
www.americanbankingnews.com - April 25 at 12:24 AM
ValuEngine Upgrades Portola Pharmaceuticals (PTLA) to HoldValuEngine Upgrades Portola Pharmaceuticals (PTLA) to Hold
www.americanbankingnews.com - April 23 at 11:18 PM
William Blair Comments on Portola Pharmaceuticals Q1 2018 Earnings (PTLA)William Blair Comments on Portola Pharmaceuticals' Q1 2018 Earnings (PTLA)
www.americanbankingnews.com - April 18 at 7:42 AM

SEC Filings

Portola Pharmaceuticals (NASDAQ:PTLA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Portola Pharmaceuticals (NASDAQ:PTLA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Portola Pharmaceuticals (NASDAQ PTLA) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.